Anisur Rahman
@anisurrahman.bsky.social
Rheumatologist and scientist. Lifelong Bristol Rovers fan. Occasional poet.
An amazing achievement.An idea that came out of a fishbowl discussion at a conference made realistic by @lupuseurope.
June 18, 2025 at 1:42 AM
An amazing achievement.An idea that came out of a fishbowl discussion at a conference made realistic by @lupuseurope.
Great presentation Daniel
June 18, 2025 at 1:40 AM
Great presentation Daniel
And would like to say that this could not have been done without the expertise of Maura Griffin and Andrew Nicolaides in vascular scanning and the 100 patients with SLE who kindly consented to scanning.
April 9, 2025 at 5:51 PM
And would like to say that this could not have been done without the expertise of Maura Griffin and Andrew Nicolaides in vascular scanning and the 100 patients with SLE who kindly consented to scanning.
@georgearobinson.bsky.social, @bcellsrosser.bsky.social @bethangoulden.bsky.social , Thomas McDonnell and Muhammad Shipa who are just starting their groups. It is exciting to think what memorable and brilliant things they will achieve in the next 25 years.
April 1, 2025 at 8:18 AM
@georgearobinson.bsky.social, @bcellsrosser.bsky.social @bethangoulden.bsky.social , Thomas McDonnell and Muhammad Shipa who are just starting their groups. It is exciting to think what memorable and brilliant things they will achieve in the next 25 years.
Me value success more when it happened. I am grateful to Allah for all of it but especially for the family of people from many places who spent time working in the group and who became permanent friends. Now, as a member of @arrdept-ucldom.bsky.social I see my younger colleagues like.....
April 1, 2025 at 8:18 AM
Me value success more when it happened. I am grateful to Allah for all of it but especially for the family of people from many places who spent time working in the group and who became permanent friends. Now, as a member of @arrdept-ucldom.bsky.social I see my younger colleagues like.....
...in places where I would never otherwise had been. It has been a fantastic adventure and after all this time I still look forward to coming to work every day. I have failed many times with grant applications and paper submissions, but I failed with my friends and the experience made....
April 1, 2025 at 8:18 AM
...in places where I would never otherwise had been. It has been a fantastic adventure and after all this time I still look forward to coming to work every day. I have failed many times with grant applications and paper submissions, but I failed with my friends and the experience made....
He also talks about reactions to biologics which might reduce our enthusiasm for those drugs. Especially because early use might lead to anti-drug antibodies. Good point. And not everyone responds to early biologics.
March 7, 2025 at 2:52 PM
He also talks about reactions to biologics which might reduce our enthusiasm for those drugs. Especially because early use might lead to anti-drug antibodies. Good point. And not everyone responds to early biologics.
But then admits that it may not be more expensive than MMF. Honest but maybe unwise! So having given up what might have been his trump card he presents hypothetical cases of patients who might not need biologics (eg mild disease) or would do better on cyclophosphamide.
March 7, 2025 at 2:52 PM
But then admits that it may not be more expensive than MMF. Honest but maybe unwise! So having given up what might have been his trump card he presents hypothetical cases of patients who might not need biologics (eg mild disease) or would do better on cyclophosphamide.
She is being opposed by chriswincup.bsky.social. I am really proud of Chris because he is my PhD student and has reached a position of such respect so early in his career. First of all he has gone to cost. RTX very expensive.
Chris Wincup (@chriswincup.bsky.social)
Rheumatologist specialising in lupus based at King’s College Hospital, London 🏥 BSR, EULAR and OMERACT SLE Working Groups
chriswincup.bsky.social
March 7, 2025 at 2:52 PM
She is being opposed by chriswincup.bsky.social. I am really proud of Chris because he is my PhD student and has reached a position of such respect so early in his career. First of all he has gone to cost. RTX very expensive.
But she hasn't mentioned the much higher cost of biologics. I think that changes everything. Can it be necessary to use something that is very expensive but might be a bit better. A great argument by Mariele though.
March 7, 2025 at 2:52 PM
But she hasn't mentioned the much higher cost of biologics. I think that changes everything. Can it be necessary to use something that is very expensive but might be a bit better. A great argument by Mariele though.
She shows from trial data that remission with anifrolumab is higher immunosuppressive naive patients and they also got less herpes zoster. Maybe use biologic before immunosuppressive preliminary data from Italian lupus nephritis also shows benefit of early belimumab.
March 7, 2025 at 2:52 PM
She shows from trial data that remission with anifrolumab is higher immunosuppressive naive patients and they also got less herpes zoster. Maybe use biologic before immunosuppressive preliminary data from Italian lupus nephritis also shows benefit of early belimumab.
Not essential (Mariele clarifies). She is building a clever argument that the earlier we achieve remission in a patient with SLE, the better it would be for long-term outcome. So if biologics can give earlier remission then you can argue that they are necessary.
March 7, 2025 at 2:52 PM
Not essential (Mariele clarifies). She is building a clever argument that the earlier we achieve remission in a patient with SLE, the better it would be for long-term outcome. So if biologics can give earlier remission then you can argue that they are necessary.
And Marit, unlike Laura, does talk about the high non drug related costs as well as even higher treatment costs. Single patient adverse outcomes have large impact on share value of company. This has been a very calm and measured deconstruction of the CAR T buzz. I am voting with Marit.
March 7, 2025 at 11:32 AM
And Marit, unlike Laura, does talk about the high non drug related costs as well as even higher treatment costs. Single patient adverse outcomes have large impact on share value of company. This has been a very calm and measured deconstruction of the CAR T buzz. I am voting with Marit.
She stresses that SLE patients are young and long term toxicity could be an issue. Limited phenotype of patients suitable for this treatment. Well enough to tolerate the treatment yet also severe refractory disease. Since we don't know what drives B cell abnormality it could return after CAR T tx
March 7, 2025 at 11:32 AM
She stresses that SLE patients are young and long term toxicity could be an issue. Limited phenotype of patients suitable for this treatment. Well enough to tolerate the treatment yet also severe refractory disease. Since we don't know what drives B cell abnormality it could return after CAR T tx
So most of this is published- dramatic results in small number of patients from one centre. Laura hasn't really addressed how invasive and time consuming and expensive the treatment is.
March 7, 2025 at 11:16 AM
So most of this is published- dramatic results in small number of patients from one centre. Laura hasn't really addressed how invasive and time consuming and expensive the treatment is.
But drop in Ig not too bad and patients still respond to vaccination. Possible short term adverse effects - Cytoline Release Syndrome 60% grade 1, but very few worse than that. Also myelotoxicity and neurotoxicity and some infections.
March 7, 2025 at 11:16 AM
But drop in Ig not too bad and patients still respond to vaccination. Possible short term adverse effects - Cytoline Release Syndrome 60% grade 1, but very few worse than that. Also myelotoxicity and neurotoxicity and some infections.
They have treated patients with severe refractory SLE, SSc and myositis. N =25 so far. All got major response or remission. Only one relapsed. Huge improvement in disease activity (and remember all patients were refractory to standard treatment). Tissue B cells depleted.
March 7, 2025 at 11:16 AM
They have treated patients with severe refractory SLE, SSc and myositis. N =25 so far. All got major response or remission. Only one relapsed. Huge improvement in disease activity (and remember all patients were refractory to standard treatment). Tissue B cells depleted.
First, Laura Bucci from Erlangen where a lot of the CAR T cell work had been done, argues that it's a game changer. She goes over the method of the CAR T cell treatment and mentions that they are developing new ways of both transduction and using different cells.
March 7, 2025 at 11:16 AM
First, Laura Bucci from Erlangen where a lot of the CAR T cell work had been done, argues that it's a game changer. She goes over the method of the CAR T cell treatment and mentions that they are developing new ways of both transduction and using different cells.
I have never seen so much excitement based on so little evidence for any treatment in lupus BUT also not seen any treatment that possibly switches the disease off totally. Will be fascinating to see how this debate plays out.
March 7, 2025 at 11:16 AM
I have never seen so much excitement based on so little evidence for any treatment in lupus BUT also not seen any treatment that possibly switches the disease off totally. Will be fascinating to see how this debate plays out.
Such studies as there have been using probiotics in RA had unconvincing proof of benefits.
Zoltan gets my vote. It's more fake news than revolutionary.
Zoltan gets my vote. It's more fake news than revolutionary.
March 7, 2025 at 10:23 AM
Such studies as there have been using probiotics in RA had unconvincing proof of benefits.
Zoltan gets my vote. It's more fake news than revolutionary.
Zoltan gets my vote. It's more fake news than revolutionary.
And none really seem convincing. Multiple bacteria of microbiome have been reported to be up or down in different diseases. But does it really matter? Also questions borderline significance of results comparing microbiome in different diseases. Zoltan has been very convincing.
March 7, 2025 at 10:23 AM
And none really seem convincing. Multiple bacteria of microbiome have been reported to be up or down in different diseases. But does it really matter? Also questions borderline significance of results comparing microbiome in different diseases. Zoltan has been very convincing.